Fujian Medical University Union Hospital is conducting a multicenter phase 4 randomized control study to compare the efficacy of two different doses of intravenous immune globulin (IVIG) in the treatment of children with newly diagnosed immune thrombocytopenia, and to reduce related adverse reactions and economic burdens on the premise of ensuring the remission rate. Eligibility is restricted to those who have a platelet count below 20,000 µL and are between 28 days of age through to 14 years of age. You must also have a confirmed diagnosis of ITP and have never received treated for ITP in past.
China
Recruiting